- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00006812
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian epithelial or primary peritoneal cavity cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
- Determine the antitumor activity of capecitabine in patients with recurrent, platinum-sensitive ovarian epithelial or primary peritoneal cavity cancer.
- Determine the nature and degree of toxicity of this drug in this patient population.
OUTLINE: This is a multicenter study.
Patients receive oral capecitabine twice daily for 14 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study within 6-12 months.
Type d'étude
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Center - Calgary
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
California
-
Los Angeles, California, États-Unis, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Angeles, California, États-Unis, 90033-0804
- USC/Norris Comprehensive Cancer Center and Hospital
-
Orange, California, États-Unis, 92868
- Chao Family Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, États-Unis, 80010
- University of Colorado Cancer Center
-
-
Florida
-
Tampa, Florida, États-Unis, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Rush-Presbyterian-St. Luke's Medical Center
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202-5289
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242-1009
- Holden Comprehensive Cancer Center at the University of Iowa
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- Radiation Oncology Branch
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02111
- Tufts University School of Medicine
-
Worcester, Massachusetts, États-Unis, 01655
- University of Massachusetts Memorial Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- University of Minnesota Cancer Center
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Columbia, Missouri, États-Unis, 65203
- Ellis Fischel Cancer Center - Columbia
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Camden, New Jersey, États-Unis, 08103
- Cooper Hospital/University Medical Center
-
-
New York
-
Brooklyn, New York, États-Unis, 11203
- State University of New York Health Science Center at Brooklyn
-
New York, New York, États-Unis, 10021
- Memorial Sloan-Kettering Cancer Center
-
Stony Brook, New York, États-Unis, 11790-7775
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham, North Carolina, États-Unis, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, États-Unis, 27157-1082
- Comprehensive Cancer Center at Wake Forest University
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Taussig Cancer Center
-
Columbus, Ohio, États-Unis, 43210-1240
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73190
- University of Oklahoma College of Medicine
-
-
Pennsylvania
-
Abington, Pennsylvania, États-Unis, 19001
- Abington Memorial Hospital
-
Hershey, Pennsylvania, États-Unis, 17033
- Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, États-Unis, 19107-5541
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
-
-
Texas
-
Houston, Texas, États-Unis, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
- Histologically proven recurrent ovarian epithelial or primary peritoneal cavity cancer
Measurable disease
- At least 1 unidimensionally measurable lesion
- Ascites and pleural effusions are not considered measurable disease
Prior therapy must include 1 platinum-based chemotherapy regimen for primary disease containing carboplatin, cisplatin, or another organoplatinum compound
- Treatment-free interval of 6-12 months after response to platinum therapy
- Not eligible for higher priority GOG protocol
PATIENT CHARACTERISTICS:
Age:
- Any age
Performance status:
- GOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least lower limit of normal
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
Renal:
- Creatinine clearance at least 50 mL/min
Other:
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No neuropathy (sensory and motor) greater than grade 1
- No other malignancy within the past 5 years except nonmelanoma skin cancer
- No concurrent active infection requiring antibiotics
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 3 weeks since prior biologic or immunologic therapy
- No concurrent prophylactic filgrastim (G-CSF)
Chemotherapy:
- See Disease Characteristics
- If no prior therapy with paclitaxel, a second regimen including paclitaxel allowed
- No prior capecitabine or fluorouracil
- No prior chemotherapy for recurrent or persistent disease, including pretreatment with initial chemotherapy regimens
- Recovered from prior chemotherapy
Endocrine therapy:
- At least 1 week since prior hormonal therapy directed at malignant tumor
- Concurrent continuation of hormone replacement therapy allowed
Radiotherapy:
- At least 3 weeks since prior radiotherapy and recovered
- No prior radiotherapy to site(s) of measurable disease
- No prior radiotherapy to more than 25% of bone marrow
Surgery:
- Recovered from prior surgery
Other:
- No prior cancer treatment that would preclude study therapy
- No concurrent amifostine or other protective reagents
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Agustin Garcia, MD, University of Southern California
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000068330
- GOG-0146L
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer des ovaires
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie